Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H. Mayer, Kelly E. Seaton, Yunda Huang et al.|PLoS Medicine|2017Cited by 132
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A. Prentice, Rasmi Thomas, Philip K. Ehrenberg et al.|Science Translational Medicine|2015Cited by 54
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Jamie Sanders, Amelia R. Hofstetter et al.|npj Vaccines|2024Cited by 19